Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

By LabMedica International staff writers
Posted on 29 Aug 2026

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. More...

Blood-based non-coding RNA biomarkers are promising, yet patient heterogeneity and measurement variability can undermine their reliability. Clinical laboratories also need robust endogenous controls to standardize RNA quantification across studies. Researchers now present new findings describing a prognostic microRNA signal in elderly COVID-19 subphenotypes and a candidate long non-coding RNA reference gene for blood assays.

At the Biomedical Research Institute of Lleida (IRBLleida) and the University of Lleida, the Clinical and Molecular Phenotyping group conducted two complementary investigations focused on blood-derived non-coding RNA biomarkers. One study evaluated circulating microRNAs as prognostic indicators for hospitalized patients with COVID-19 aged over 65 years. A companion study assessed long non-coding RNAs as stable internal controls to strengthen quantification workflows in blood-based assays.

The prognostic approach integrated the circulating microRNA profile (miRNome) with routine clinical information to delineate biologically meaningful patient subphenotypes and refine mortality prediction. Analysis of hospitalized older adults identified three clinical subtypes and highlighted miR-106b-3p as a candidate marker for forecasting 90-day mortality within the subgroup burdened by multiple comorbidities. 

Incorporating this microRNA marker into clinical models improved predictive performance compared with models using clinical variables alone. In parallel, the methodological study measured the expression of dozens of long non-coding RNAs (lncRNAs) in blood from 182 individuals to identify a reliable endogenous reference; the results point to TUG1 as a stable control gene for lncRNA quantification.

The prognostic microRNA study, encompassing samples and clinical data from 763 patients older than 65 years hospitalized with COVID-19, was published in iScience on August 10, 2026. The internal-control study is published in Biomarker Research (December 30, 2025). Collaborations included the Translational Research in Respiratory Medicine group; healthcare professionals and researchers at Arnau de Vilanova and Santa Maria University Hospitals in Lleida; and the Biomedical Research Institute of Salamanca (IBSAL).

Together, the findings support the utility of non-coding RNA readouts to enhance risk stratification in vulnerable respiratory cohorts and to standardize RNA measurements across laboratories. The authors note that one line of work advances prognostic biomarker discovery while the other provides a methodological foundation to improve reproducibility and comparability in future blood-based RNA studies.

“These findings reinforce the idea that molecular biomarkers can complement traditional clinical information and contribute to more accurate risk stratification in particularly vulnerable populations,” explained Manel Pérez Pons, first author of the article and researcher at IRBLleida.

“Having a robust reference is essential to ensure that detected biomarkers reflect genuine biological changes rather than technical variations in laboratory procedures,” said Carlos Rodríguez Muñoz, first author of the article and researcher at IRBLleida.

Related Links:
IRBLleida


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Urine Analyzer
respons® UDS100
New
Gold Member
Connectivity Solution
EKF Link
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.